AtriCure, Inc. (NASDAQ:ATRC) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ATRC to report 3Q20 loss of $ 0.34 per share from revenue of $ 49.37 million.
For the full year, analysts anticipate top line of $ 205.45 million, while looking forward to loss of $ 1.27 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 254.00 million ~ $ 261.00 million, where as bottomline are predicted in a range of $ -1.24 ~ $ -1.14 per share
Click Here For More Historical Outlooks Of AtriCure, Inc.
Previous Quarter Performance
AtriCure, Inc. posted loss for the second quarter of $ 0.38 per share, from the revenue of $ 40.82 million. According to street consensus, ATRC was expected to report 2Q20 loss of $ 0.57 per share from revenue of $ 35.95 million. The bottom line results beat street analysts by $ 0.19 or 33.33 percent, at the same time, top line results outshined analysts by $ 4.87 million or 13.55 percent.
Stock Performance
Shares of AtriCure, Inc. traded low $ -0.35 or -0.95 percent on Wednesday, reaching $ 36.65 with volume of 463.80 thousand shares. AtriCure, Inc. has traded high as $ 37.65 and has cracked $ 35.99 on the downward trend
The closing price of $ 36.65, representing a 59.69 % increase from the 52 week low of $ 23.17 and a 28.52 % decrease over the 52 week high of $ 51.76.
The company has a market capital of $ 1.65 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
AtriCure, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.atricure.com
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
